April 27, 2022
Article
Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.
April 26, 2022
An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.
Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
April 25, 2022
During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.
One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.
April 23, 2022
Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.
July 14, 2021
The MOVe-OUT study will continue to the phase 3 portion and evaluate 800 mg of the therapy administered twice daily.
July 13, 2021
Those taking methotrexate had lower seroconversion rates compared to controls.
July 12, 2021
While infection risk is not eliminated, the vaccine still provided significant protection.
The second wave in South Africa was larger and saw the Beta lineage dominate.
Monkeypox Symptoms in London Patients Differ from Prior Outbreaks
How COVID-19 Infiltrates and Inflames the Heart
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Communities With More Racial Prejudice Have Worse Health Outcomes
